Full CoverageAll coverage
Biogen CEO says $56,000 annually for Alzheimer’s drug is 'fair,' promises not to hike price for at least 4 years
By Berkeley Lovelace & Berkeley Lovelace Jr.
Alzheimer’s Drug Poses a Dilemma for the F.D.A. (Published 2021)
By Pam Belluck & Rebecca Robbins
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients
By Deena Beasley & Julie Steenhuysen
Biogen Soars as Alzheimer’s Approval Cheers Investors
By Robert Langreth
New Alzheimer’s drug is 1st of its kind to be FDA approved
By Sony Salzman
Alzheimer’s drug from Biogen wins US approval
By Nikou Asgari
'The price is bewildering': The cost of Biogen's Alzheimer's drug may lead payers to erect roadblocks
By Ed Silverman
An extra twist in the FDA’s Alzheimer’s decision: no limits on which patients can get the drug
By Andrew Joseph
FAQs: What you need to know about the Alzheimer’s drug Aduhelm
By Elizabeth Cooney
Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense (Published 2021)
By Pam Belluck & Rebecca Robbins
F.D.A. Approves Alzheimer’s Drug Despite Fierce Debate Over Whether It Works (Published 2021)
By Pam Belluck & Rebecca Robbins